Castle Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CSTL | PSNL | NEO | BDSX | BLLN | MYGN | |
|---|---|---|---|---|---|---|
| Market cap | 1.09B | 1.69B | 2.22B | 226.74M | 5.37B | 575.81M |
| P/E (TTM) | — | — | — | — | 180.8 | — |
| Forward P/E | -38.2 | -16.3 | 54.5 | -97.7 | 76.7 | -10.2 |
| Price/book | 2.3 | 6.2 | 2.8 | 24.8 | 9.9 | 1.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +4.68% | +105.61% | +61.36% | +144.77% | +1.39% | −8.21% |
| Today | +1.74% | +0.25% | +1.90% | +2.09% | +3.11% | −0.33% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All CSTL news ›Hainan Haiyao plans to unload stake in SinoMab BioScience
Hainan Haiyao Co Ltd: Says co plans to unload up to 5% stake in SinoMab BioScience Ltd ... Hainan Haiyao Co., Ltd. Hainan Haiyao plans to unload stake in SinoMab BioScience Published on 04/03/2026 at 09:33 am EDT
Castle Biosciences (NASDAQ:CSTL) Stock Gets Downgrade from Wall Street Zen
Posted by Michael Walen on Oct 26th, 2026 Castle Biosciences (NASDAQ:CSTL – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday, Wall…
Castle Biosciences CEO sells 14,496 shares
Castle Biosciences (CSTL) is a Nasdaq-listed diagnostics company focused on molecular tests for dermatologic and gastroenterological diseases and skin cancers. - [Form 4] CASTLE BIOSCIENCES INC Insider Trading Activity Castle Biosciences…
Castle Biosciences Juvenal sells 3,288 shares
INVE Technologies Announces the Commencement of a $20 Million Modified Dutch Auction Tender Offer for its Common Stock Nexera Technologies: Fort Technology’s Subsidiary Logia USA Signs Exclusive Distribution Agreement to Expand Fuel…
Castle Biosciences COO sells 4,153 shares
Castle Biosciences (CSTL) is a Nasdaq-listed diagnostics company focused on molecular tests for dermatologic and gastroenterological diseases and skin cancers. - [Form 4] CASTLE BIOSCIENCES INC Insider Trading Activity Castle Biosciences…
PGDx elio® tissue complete CDx Brings Speed and Confidence to Advanced Melanoma BRAF Testing
FDA approval establishes Labcorp’s PGDx elio tissue complete CDx as a trusted companion diagnostic for advanced melanoma Sponsored content brought to you by For oncologists treating advanced melanoma, time is the most unforgiving variable.…
Head-To-Head Comparison: HealthEquity (NASDAQ:HQY) versus Castle Biosciences (NASDAQ:CSTL)
Posted by Sarita Garza on Oct 13th, 2026 HealthEquity (NASDAQ:HQY – Get Free Report) and Castle Biosciences (NASDAQ:CSTL – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Has Consensus Target Price of $42.00 According to Brokerages
Read Our Latest Report on Castle Biosciences Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to provide personalized information for patients with cancer and other serious…
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
Healthcare Triangle, Inc. Announces 1-for-20 Reverse Stock Split as Part of Nasdaq Compliance Plan Greenland Energy Company Announces the Resignation of Roderick McIllree From the Board of Directors BlackRock Capital Allocation Term Trust…
Castle Biosciences officer proposes $431K share sale
Castle Biosciences (CSTL) is a Nasdaq-listed diagnostics company focused on molecular tests for dermatologic and gastroenterological diseases and skin cancers. Castle Biosciences officer proposes $431K share sale Goldman Sachs & Co. LLC is…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net7
- themarketsdaily.com2
- defenseworld.net1
- marketbeat.com1
- marketscreener.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.